ERBB2 and breast carcinoma: Furthermore, PATZ1 is targeted by miR-29b, a microRNA biomarker for the HER2-enriched subtype, with its expression negatively associated with this subtype, and overexpression of miR-29b inhibits breast cancer cell proliferation and induces apoptosis primarily by downregulating STAT3 protein levels [48,49].